Hydroxymethylnitrofurazone lymphatic uptake with nanostructured lipid carrier after oral administration in rats.
Nanomedicine (Lond)
; 19(4): 293-301, 2024 02.
Article
em En
| MEDLINE
| ID: mdl-38270378
ABSTRACT
Background:
Leishmaniasis, caused by the protozoan Leishmania sp., infects phagocyte cells present in lymphatic organs. This study demonstrates the influence of nanostructured lipid carrier-loaded hydroxymethylnitrofurazone (NLC-NFOH) on lymphatic uptake using a chylomicron-blocking flow model in rats.Method:
Lymphatic uptake of NFOH was assessed 1 h after oral administration of dimethyl sulfoxide with NFOH or NLC-NFOH with and without cycloheximide pretreatment.Result:
Dimethyl sulfoxide with NFOH and NLC-NFOH showed NFOH serum concentrations of 0.0316 and 0.0291 µg/ml, respectively. After chylomicron blocking, NFOH was not detected.Conclusion:
Despite log P below 5, NFOH was successfully taken up by the lymphatic system. Long-chain fatty acids and particle size might be main factors in these findings. NLC-NFOH is a promising and convenient platform for treating leishmaniasis via oral administration.Palavras-chave
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Leishmaniose
/
Nanoestruturas
/
Nitrofurazona
Tipo de estudo:
Prognostic_studies
Limite:
Animals
Idioma:
En
Revista:
Nanomedicine (Lond)
Ano de publicação:
2024
Tipo de documento:
Article
País de afiliação:
Brasil
País de publicação:
Reino Unido